I completely agree with your analysis. NP's numbe
Post# of 148188
(Total Views: 490)
Posted On: 05/10/2020 9:38:29 PM
I completely agree with your analysis. NP's number one priority right now is completing enrollment in the 75 patient phase 2 trial; he basically said that in the investors' cc two Mondays ago. This is the lane that Leronlimab can have all to itself, while Remdesevir has the severely ill patient lane all to itself (for the time being).
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼